1. Scrip
  2. >>Business
  3. >>Deals

AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space

 
• By Joseph Haas

Despite writing down $4bn after the failure of Stemcentrx’s Rova-T, AbbVie will bet big again on the cancer antibody-drug conjugate space by paying a high premium for ImmunoGen, including Elahere and its R&D potential.

AbbVie Sign
AbbVie is ready to make another play in the ADC space with ImmunoGen deal • Source: Shutterstock

AbbVie Inc. took a big dive into the increasingly popular antibody-drug conjugate space on 30 November with a $10.1bn buyout offer for ImmunoGen, Inc. and its ovarian cancer ADC Elahere. It also took an attractive takeover option off the board in a field where the Chicago-area big pharma has long wanted to build a significant presence.

Key Takeaways

  • AbbVie will pay $10.1bn to acquire ImmunoGen and Elahere, the first antibody-drug conjugate approved to treat ovarian cancer.

The deal comes six-years after AbbVie made an ill-fated $5.8bn wager on Stemcentrx and its DLL3-targeting ADC candidate for lung...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

 
• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Kymera Inks CDK2 Deal With Gilead

 
• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

More from Business